Insilico Medicine Unveils Frontier AI Models to Accelerate Drug Discovery

Insilico Medicine announced release of its latest frontier AI models designed to generate novel drug candidates, claiming the system can evaluate millions of molecular structures in days rather than months and accelerate lead optimization through in‑silico simulations.

Bora Pharmaceuticals entered a strategic partnership with Insilico, planning to apply the new AI platform to its oncology pipeline, aiming to cut pre‑clinical testing time by up to 50 percent and fast‑track targeted therapy candidates in their first joint project.

Novartis reported that integrating AI tools similar to Insilico’s models has already shortened its internal drug discovery timelines, with early‑stage projects moving from concept to lead identification in half the usual period and the company targeting broader rollout within the next two years.

Industry analysts estimate that AI‑driven drug discovery could reduce overall R&D costs by billions, projecting a market shift as more firms adopt these models to accelerate bringing therapies to patients, with the sector valued at $9.36 billion by 2030.